Abstract: The invention relates to the use of 4,6,4?-trimethylangelicin (TMA) and structural analogs thereof to prepare a medicament for the treatment of cystic fibrosis with the primary objective of correcting the defective CFTR in a sub-group of cystic fibrosis patients consisting of patients carrying the F508del-CFTR mutation.
Type:
Grant
Filed:
June 13, 2012
Date of Patent:
March 15, 2016
Assignees:
Azienda Ospedaliera Universitaria Integrata di Verona, Universita' degli Studi di Ferrara, Universita' degli Studi di Bari, Rare Partners S.r.l.
Abstract: The invention relates to the use of 4,6,4?-trimethylangelicin (TMA) and structural analogues thereof to prepare a medicament for the treatment of cystic fibrosis with the primary objective of correcting the defective CFTR in a sub-group of cystic fibrosis patients consisting of patients carrying the F508de1-CFTR mutation.
Type:
Application
Filed:
June 13, 2012
Publication date:
October 15, 2015
Applicants:
AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA DI VERONA, RARE PARTNERS S.R.L., UNIVERSITA' DEGLI STUDI DI BARI, UNIVERSITA' DEGLI STUDI DI FERRARA